Long Term Remission of Capillary Leak Syndrome Associated with Monoclonal Gammopathy with Progression to Multiple Myeloma After Autologous Stem Cell Transplantation: a Case Report and Review of the Literature

• Published in: Oncology and therapy Vol. 12; no. 1; pp. 183 - 188
• Main Authors: Hermida, Gerardo, Alvarez-Nuño, Rodolfo, San Miguel-Izquierdo, Jesús, González-Quijada, Santiago, González-López, Tomás José
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.03.2024; Adis, Springer Healthcare
• Subjects: Autologous stem cell transplantation; Capillary leak syndrome (CLS); Case Report; Internal Medicine; Medicine; Medicine & Public Health; Monoclonal gammopathy; Multiple mieloma; Capillary leak syndrome (CLS); Monoclonal gammopathy; Multiple mieloma; Autologous stem cell transplantation
• ISSN: 2366-1070; 2366-1089
• DOI: 10.1007/s40487-024-00263-w

Background Clarkson’s disease is a very rare entity characterised by acute episodes of systemic oedema and severe hypotension associated with paraproteinaemia. Its classical treatment relies on methylxanthine combined with terbutaline. Although this prophylactic therapy reduces the mortality rate, relapses are frequent. Eighty percent of patients with Clarkson’s disease present with monoclonal gammopathy of unknown significance (MGUS). The risk of progression to multiple myeloma is 1% per year. Case Description Here, we present a 49-year-old woman who suffered multiple such episodes requiring treatment in the intensive care unit. Treatment with terbutaline and theophylline was ineffective. She was diagnosed with multiple myeloma (MM) 8 years after the first of these acute episodes. Antimyeloma treatment with bortezomib and dexamethasone was started, followed by autologous haemopoietic transplantation, with no further acute episodes since then. Conclusion Our case is, to our knowledge, unique because eradication of MM was followed by complete disappearance of acute episodes of capillary leakage. Our case report is also the first to support the use of bortezomib and dexamethasone in this setting. Furthermore, autologous peripheral blood progenitor cell transplantation consolidated the MM stringent complete remission achieving a very long progression-free survival (> 11 years) of both MM and Clarkson’s disease.